Limb-Girdle Muscular Dystrophy: Prominent Emerging Therapies by Key Players Including Sarepta, Atyr Pharma, and Catabasis to Change the Therapeutics Market Prospects in the Coming Years

Limb-Girdle-Muscular-Dystrophy-LGMD-Market-CAGR-Size-Share-Trends-Growth-Analysis

DelveInsight’s Limb-Girdle Muscular Dystrophy (LGMD) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Limb-Girdle Muscular Dystrophy market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward. 

Some of the key highlights from the Limb-Girdle Muscular Dystrophy Market Insights: 

  • According to the Orphanet, the estimated prevalence for all forms of LGMD ranges from 1/44,000 to 1/123,000. It is difficult to determine the prevalence of limb-girdle muscular dystrophy as its features vary and overlap with those of other muscle disorders.
  • As per the National Organization for Rare Disorders, the estimated range of prevalence is 1 in 14,500-123,000. The relative frequencies of the different types of LGMD vary from population to population, but worldwide LGMD2G, 2H, and 2J are extremely rare.
  • Males and females are affected in equal numbers by Limb-Girdle Muscular Dystrophy and also the age of onset can vary greatly even among individuals of the same family.
  • To fulfill the treatment gap, at present some of the pharmaceutical companies in the Limb-Girdle Muscular Dystrophy market such as Sarepta Therapeutics, Catabasis Pharmaceuticals, aTyr Pharma, ML Bio Solutions, and others are involved in the development of therapies.  
  • The key therapies expected to launch in the Limb-Girdle Muscular Dystrophy market include SRP-9005, CAT-1004, SRP-9003, ATYR1940, BBP-418, and others.
  • The key factors such as a rise in the number of prevalent cases of Limb Girdle Muscular Dystrophy, Increasing awareness about available treatment options, promising emerging pipeline therapies, and a better understanding of disease pathogenesis are expected to drive the LGMD market growth in the upcoming years. 

Learn more by requesting for sample @ Limb-Girdle Muscular Dystrophy Market Landscape 

Limb-Girdle Muscular Dystrophy: Overview 

The Limb-Girdle Muscular Dystrophy encompasses a group of rare progressive genetic disorders that cause weakness and wasting of the muscles of the hip and shoulder areas (limb-girdle area). Being a progressive disease it can affect other muscles of the body. More than 30 subtypes for LGMD exist. The symptoms, severity, age of onset, and features of disease vary among the many subtypes of this condition. 

For more insights into Disease, causes, and treatment, reach out @ Limb-Girdle Muscular Dystrophy Treatment Landscape 

Limb-Girdle Muscular Dystrophy Epidemiology Segmentation

The Limb-Girdle Muscular Dystrophy Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Total prevalent Cases of LGMD
  • Type-specific prevalent Cases of LGMD
  • Gender-specific prevalent Cases of LGMD
  • Diagnosed and Treatable cases of LGMD

Visit for more @ Limb-Girdle Muscular Dystrophy Epidemiological Insights 

Limb-Girdle Muscular Dystrophy Market

At present, there is no cure for any form of LGMD. Treatment approaches aimed at the specific symptoms present in each individual such as physical and occupational therapy. Similarly, various devices such as canes, braces, walkers, wheelchairs, and others are used to assist with walking (ambulation) and mobility. In some cases, surgery is also employed to correct skeletal abnormalities such as scoliosis. 

To fulfill the unmet needs, some of the key companies such as PTC Therapeutics, Sarepta Therapeutics, aTyr Pharma, and others are currently working toward therapeutics development. Moreover, some of the companies are also exploring the potential of Gene therapy using vectors based on the Adeno-associated Virus as a viable treatment option in the coming years. 

Limb-Girdle Muscular Dystrophy Pipeline Therapies and Key Companies 

  • SRP-9005: Sarepta Therapeutics
  • CAT-1004: Catabasis Pharmaceuticals
  • SRP-9003: Sarepta Therapeutics
  • ATYR1940: aTyr Pharma
  • BBP-418: ML Bio Solutions

For more information, visit Limb-Girdle Muscular Dystrophy Market Analysis, Patient Pool, and Emerging Therapies 

Limb-Girdle Muscular Dystrophy Market Drivers 

  • Rising awareness
  • Promising emerging pipeline therapies
  • A better understanding of disease pathogenesis
  • Increasing prevalence of Limb-Girdle Muscular Dystrophy

Scope of the Report

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Limb-Girdle Muscular Dystrophy (LGMD), covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight into Limb-Girdle Muscular Dystrophy (LGMD) epidemiology and treatment in the 7MM
  • Current and emerging therapies for Limb-Girdle Muscular Dystrophy (LGMD) 
  • Limb-Girdle Muscular Dystrophy (LGMD) market drivers and barriers

Key Questions Answered in the Report

  • What was the Limb-Girdle Muscular Dystrophy (LGMD) market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Limb-Girdle Muscular Dystrophy (LGMD) total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Limb-Girdle Muscular Dystrophy (LGMD) market size during the forecast period (2018-2030)?
  • At what CAGR, the Limb-Girdle Muscular Dystrophy (LGMD) market is expected to grow in 7MM during the forecast period (2018-2030)?

Get in touch with our Business executive @ Limb-Girdle Muscular Dystrophy (LGMD) Market Landscape Analysis 

Table of Contents 

1

Key Insights

2

Report Introduction

3

Competitive Intelligence Analysis for Limb-Girdle Muscular Dystrophy

4

Limb-Girdle Muscular Dystrophy Market Overview at a Glance

5

Executive Summary of Limb-Girdle Muscular Dystrophy

6

Limb-Girdle Muscular Dystrophy Epidemiology and Market Methodology

7

Limb-Girdle Muscular Dystrophy Epidemiology and Patient Population

8

Limb-Girdle Muscular Dystrophy Patient Journey

9

Treatment Algorithm, Current Treatment, and Medical Practices

10

Key Endpoints in Limb-Girdle Muscular Dystrophy Clinical Trials

11

Limb-Girdle Muscular Dystrophy Marketed Therapies 

12

Limb-Girdle Muscular Dystrophy Emerging Therapies

13

Limb-Girdle Muscular Dystrophy: 7 Major Market Analysis

14

Attribute analysis

15

Access and Reimbursement Overview of Limb-Girdle Muscular Dystrophy

16

KOL Reviews

17

Case Reports

18

Limb-Girdle Muscular Dystrophy Market Drivers

19

Limb-Girdle Muscular Dystrophy Market Barriers

20

SWOT Analysis

21

Disclaimer

22

DelveInsight Capabilities

23

About DelveInsight

Learn more about the report offerings @ Limb-Girdle Muscular Dystrophy Market Outlook

Latest Healthcare Reports –

Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast
DelveInsight’s Limb Girdle Muscular Dystrophy (LGMD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Limb Girdle Muscular Dystrophy (LGMD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Limb Girdle Muscular Dystrophy (LGMD) Pipeline Insights
Limb Girdle Muscular Dystrophy (LGMD) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy (LGMD) market.

Emphysema Market
DelveInsight’s “Emphysema Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Emphysema market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Hypercalcemia Market
DelveInsight’s “Hypercalcemia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypercalcemia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Anti-hypertension Market
DelveInsight’s “Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Anti-hypertension market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Healthcare Blogs – 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter